PlainPharmaWatch
CMS PY 2024 Company profile Open Payments data

SUPERNUS PHARMACEUTICALS, INC.

SUPERNUS PHARMACEUTICALS, INC. reported $4.4M in payments to physicians and teaching hospitals across 61,251 transactions in CMS Open Payments PY 2024.

Pharmaceutical payment transparency data for SUPERNUS PHARMACEUTICALS, INC.. Ranked #280 of 1,797 companies by total payments. Source: CMS Open Payments, Program Year 2024.

Payment Overview

Total Payments

$4.4M

0.0% of all payments

Transactions

61,251

$71.39 avg

Recipients

61,251

$71.39 avg

Industry Rank

#280

of 1,797 companies

What the Data Shows for SUPERNUS PHARMACEUTICALS, INC.

In Program Year 2024, SUPERNUS PHARMACEUTICALS, INC. reported $4,372,425.79 in payments to 61,251 physicians and teaching hospitals across 61,251 individual transactions — an average of $71.39 per transaction and $71.39 per recipient. That total places SUPERNUS PHARMACEUTICALS, INC. at rank #280 out of 1,797 companies in the CMS Open Payments database, representing 0.0% of all industry payments reported nationwide for the year. Payment volume at this scale is characteristic of manufacturers with broad prescriber engagement, active clinical research programs, or patented therapies generating ongoing royalty obligations.

The payment mix for SUPERNUS PHARMACEUTICALS, INC. spans 5 distinct categories defined by CMS — including general payments (consulting, speaker fees, meals, travel), research payments tied to clinical trials, and ownership or investment interests. The largest single category is "Food and Beverage" at $1.8M, accounting for 41.3% of the company's reported total and 58,526 transactions. This distribution matters because different payment types carry different regulatory and ethical implications: research funding supports clinical development, while general payments like meals and speaker fees have been studied for their correlation with prescribing patterns in peer-reviewed journals such as JAMA Internal Medicine.

Recipient concentration is another useful lens. The top 5 recipients of payments from SUPERNUS PHARMACEUTICALS, INC. received $0.00 combined — 0.0% of the company's total — with the remaining 100.0% distributed across the rest of the 61,251 recipients. A relatively distributed top-5 share suggests broader engagement across the prescriber community rather than concentration among a handful of high-value relationships. All figures above are drawn directly from the CMS Open Payments Public Use Files for PY2024 and are disclosed under the Physician Payments Sunshine Act; this page summarizes reported financial transfers and does not represent medical advice or judgment about individual prescribing decisions.

Payment Breakdown by Type

SUPERNUS PHARMACEUTICALS, INC. made 5 types of payments. "Food and Beverage" accounts for 41.3%.

Food and Beverage $1.8M

41.3% · 58,526 transactions

Compensation for Services Other Than Consulting $1.7M

38.1% · 914 transactions

Honoraria $591.8K

13.5% · 204 transactions

Travel and Lodging $307.5K

7.0% · 1,598 transactions

Education $56.87

0.0% · 9 transactions

Payment Type Amount Transactions
Food and Beverage $1.8M 58,526
Compensation for Services Other Than Consulting $1.7M 914
Honoraria $591.8K 204
Travel and Lodging $307.5K 1,598
Education $56.87 9

Payment Size Analysis

Average transaction size: $71.39. Average per recipient: $71.39.

Total Amount

$4,372,425.79

Avg per Transaction

$71.39

Avg per Recipient

$71.39

Payment Transparency Context

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.3B

across 1,797 companies

SUPERNUS PHARMACEUTICALS, INC. Share

0.0%

#280 by total payments

Frequently Asked Questions

How much did SUPERNUS PHARMACEUTICALS, INC. pay to physicians and hospitals in 2024?
SUPERNUS PHARMACEUTICALS, INC. made $4,372,425.79 in payments to physicians and hospitals in Program Year 2024, across 61,251 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from SUPERNUS PHARMACEUTICALS, INC.?
SUPERNUS PHARMACEUTICALS, INC. made payments to 61,251 physicians and teaching hospitals in 2024. The average payment per recipient was $71.39.
What types of payments did SUPERNUS PHARMACEUTICALS, INC. make?
SUPERNUS PHARMACEUTICALS, INC. made 5 different types of payments. The largest category was "Food and Beverage" at $1.8M, representing 41.3% of all payments.
How does SUPERNUS PHARMACEUTICALS, INC. rank among pharmaceutical companies?
SUPERNUS PHARMACEUTICALS, INC. ranks #280 out of 1,797 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from SUPERNUS PHARMACEUTICALS, INC.?
The average transaction from SUPERNUS PHARMACEUTICALS, INC. was $71.39 in 2024. The company made 61,251 total transactions to 61,251 recipients.
Are the top recipients concentrated for SUPERNUS PHARMACEUTICALS, INC.?
The top 5 recipients received $0.00 from SUPERNUS PHARMACEUTICALS, INC., representing 0.0% of the company's total payments. Payments are relatively well-distributed across recipients.
Where does the payment data for SUPERNUS PHARMACEUTICALS, INC. come from?
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.3B across 1,797 companies.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.